Chad Messer

Lake Street Capital Markets

Recent Articles about Coya Therapeutics Inc.

Is This Biopharmaceutical Co. Developing ALS Drug a Buy? 08/25/2026

Read to find out what analysts think of Houston-based Coya Therapeutics Inc. (COYA:NASDAQ), which is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative, autoimmune, and metabolic diseases.

Coya Therapeutics Advances Phase 2 ALSTARS ALS Trial Toward 2026 Enrollment Finish 08/25/2026

Coya Therapeutics moves COYA 302 through Phase 2 ALSTARS for ALS with enrollment completion expected in 2026 and topline data in Q1 2027. Learn key catalysts, pipeline details, and analyst targets.